Immunovia AB (publ) announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray(TM) PanCan-d test. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees. The Company will provide an update once the consultation process is concluded.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.452 SEK | -1.76% | +1.54% | -18.06% |
05-21 | Immunovia Seeks SEK70 Million from Proposed Rights Offering | MT |
04-29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 |
1st Jan change | Capi. | |
---|---|---|
-18.06% | 6.24M | |
-26.77% | 16.48B | |
-43.46% | 2.79B | |
+22.46% | 1.94B | |
-12.32% | 1.46B | |
+31.49% | 1.33B | |
-16.15% | 966M | |
+1.33% | 791M | |
-31.07% | 788M | |
-25.95% | 620M |
- Stock Market
- Equities
- IMMNOV Stock
- News Immunovia AB
- Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test